Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
18 juin 2024 07h00 HE
|
Immunocore Holdings plc
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma ...
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
03 juin 2024 08h00 HE
|
Evaxion Biotech
Evaxion’s AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melanoma patientsFindings further confirm and validate the precision and...
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
31 mai 2024 16h05 HE
|
Immunocore Holdings plc
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy...
ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024
30 mai 2024 08h00 HE
|
ImCheck Therapeutics SAS
ImCheck to Present Promising ICT01 Datafrom the EVICTION Study at ASCO 2024 Interim data from Phase I/II EVICTION study shows favorable safety profile and promising efficacy for ICT01 in combination...
Immuneering to Present at the Jefferies Global Healthcare Conference
29 mai 2024 16h05 HE
|
Immuneering Corporation
Immuneering to Present at the Jefferies Global Healthcare Conference
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
07 mai 2024 16h05 HE
|
Immuneering Corporation
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
Immuneering Recognizes Melanoma Awareness Month
06 mai 2024 16h30 HE
|
Immuneering Corporation
Immuneering Recognizes Melanoma Awareness Month
Immunocore announces upcoming presentation and posters at ASCO 2024
24 avr. 2024 10h00 HE
|
Immunocore Holdings plc
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be...
[Latest] Global Pet Cancer Therapeutics Market Size/Share Worth USD 1,162.4 Million by 2033 at a 9.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
08 avr. 2024 13h30 HE
|
Custom Market Insights
Austin, TX, USA, April 08, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Pet Cancer Therapeutics Market Size, Trends and Insights By Therapy...
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03 avr. 2024 16h05 HE
|
Immuneering Corporation
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference